双环醇片联合恩替卡韦治疗慢性乙型肝炎疗效及对患者肝功能的保护作用  

Curative effect of bicyclic alcohol tablets combined with entecavir in treatment of chronic hepatitis B and its protective effect on liver function

作　　者：李娟[1] 曹平虎 唐先梅[1] 何旭[1] 王婷[1] LI Juan;CAO Pinghu;TANG Xianmei;HE Xu;WANG Ting(Hanzhong Central Hospital,Hanzhong 723000,China)

机构地区：[1]汉中市中心医院,陕西汉中723000

出　　处：《陕西医学杂志》2021年第10期1271-1274,共4页Shaanxi Medical Journal

基　　金：陕西省重点研发计划项目(2019SF-148)。

摘　　要：目的:研究双环醇片联合恩替卡韦治疗慢性乙肝的疗效及对患者肝功能的保护作用。方法:选取136例慢性乙肝患者为研究对象,采用随机数字法分为对照组(n=68)和观察组(n=68),对照组给予恩替卡韦治疗,观察组在对照组基础上给予双环醇片治疗,比较两组临床疗效、乙肝表面抗原(HBsAg)、乙型肝炎e抗原(HBeAg)、HBV-DNA转阴率、肝功能指标[丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)、白蛋白(ALB)]、肝纤维化指标[透明质酸酶(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)]、免疫功能及不良反应发生率。结果:观察组治疗有效率高于对照组(91.18%与76.47%,P<0.05);治疗后观察组HBV-DNA转阴率高于对照组(P<0.05);治疗后两组ALB、CD3、CD 4、CD4/CD8均升高,HBsAg、HBeAg、ALT、AST、TBIL、HA、LN、Ⅳ-C、PCⅢ、CD8均降低(P<0.05),且观察组ALB、CD3、CD4、CD4/CD8高于对照组,HBsAg、HBeAg、ALT、AST、TBIL、HA、LN、Ⅳ-C、PCⅢ、CD8低于对照组(均P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:双环醇片联合恩替卡韦治疗慢性乙肝的疗效显著,可抑制HBsAg、HBeAg分泌,改善肝功能,延缓纤维化进展,提高免疫功能,且安全性较高。Objective:To study the curative effect of bicyclic alcohol tablets combined with entecavir in the treatment of chronic hepatitis B and its protective effect on liver function.Methods:136 patients with chronic hepatitis B were selected and divided into control group(n=68)and observation group(n=68)by random number table method.The control group was treated with entecavir,and the observation group was treated with bicyclic alcohol tablets combined with entecavir.Clinical effects,negative conversion rates of hepatitis B surface antigen(HBsAg),hepatitis B e antigen(HBeAg)and HBV-DNA,liver function indicators[alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL),albumin(ALB)],liver fibrosis indicators[hyaluronidase(HA),laminin(LN),typeⅢprocollagen(PCⅢ),typeⅣcollagen(Ⅳ-C)],immune function,and the incidence of adverse reactions were compared between the two groups.Results:The effective rate of treatment in the observation group was higher than that in the control group(91.18%vs.76.47%,P<0.05).After treatment,the negative conversion rate of HBV-DNA in the observation group was higher than that in the control group(P<0.05).After treatment,ALB,CD3,CD4,and CD4/CD8 were increased,HBsAg,HBeAg,ALT,AST,TBIL,HA,LN,Ⅳ-C,PCⅢ,and CD8 were reduced in the two groups(all P<0.05).ALB,CD3,CD4,and CD4/CD8 in the observation group were higher than those in the control group,while HBsAg,HBeAg,ALT,AST,TBIL,HA,LN,Ⅳ-C,PCⅢ,and CD8 were lower than those in the control group(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Bicyclic alcohol tablets combined with entecavir is effective in the treatment of chronic hepatitis B.The combined treatment can inhibit the secretion of HBsAg and HBeAg,improve liver function,delay the progression of fibrosis,and improve immune function,with high safety.

关 键 词：慢性乙肝 双环醇片 恩替卡韦 肝功能 肝纤维化 免疫功能 

分 类 号：R575.1[医药卫生—消化系统]